Notes on Chapter 5: Catecholamines
Chapter 5: Catecholamines
Overview
- Main Focus: Understanding catecholamine synthesis, release, inactivation, and their related systems.
- Catecholamines include:
- Dopamine (DA)
- Norepinephrine (NE)
- Epinephrine (Epi)
- Conceptual Framework:
- Neurotransmitter Lifecycle:
- Function/Organization
- Synthesis
- Packaging/Storage
- Release
- Inactivation
Introduction
- Significance of Abnormal Function Studies:
- Provides insight into normal functions.
- Must maintain professionalism and empathy in discussions.
- Example Study: Dopamine-deficient mouse model by Richard Palmiter, UW Biochemistry.
- Key Findings:
- Dopamine-deficient mice are:
- Severely hypoactive
- Adipsic (lack of thirst)
- Aphagic (lack of hunger)
- Original Model: Inactivating tyrosine hydroxylase (TH) gene and restoring TH function ameliorated conditions with L-DOPA administration.
- Bottom Line: Fundamentals of the catecholamine system illuminate the outcomes observed in the model.
Catecholamine Synthesis
- Precursor: Tyrosine from dietary protein.
- Rate-limiting enzyme: Tyrosine hydroxylase (TH).
- Synthesis Pathway:
- Tyrosine to DOPA conversion is slower than other steps.
- TH activity regulated by:
- Levels of DA and NE (high amounts in terminals reduce activity).
- Rate of cell firing via second messengers.
- Modification Strategies:
- Increase synthesis rate using biological precursors such as L-DOPA.
- Decrease synthesis rate by enzyme inhibition (e.g., AMPT).
Catecholamine Storage and Release
- Vesicular Packaging: Protects NT from degradation by enzymes.
- Transport facilitated by:
- Vesicular Monoamine Transporter (VMAT):
- VMAT1 present in adrenal medulla.
- VMAT2 present in the brain.
- Blockage: Reserpine blocks VMAT, leading to decreased catecholamine levels due to heightened breakdown by metabolizing enzymes.
- Historical Context:
- Arvid Carlsson (1957): Proposed the catecholamine theory of depression.
Catecholamine Release Mechanisms
- Autoreceptors:
- Located on dopaminergic neurons.
- Inhibit release through voltage-gated channels.
- Example: Clonidine stimulates NE autoreceptors.
- Drugs like amphetamine and methamphetamine induce release of catecholamines regardless of cell firing and block reuptake:
- Result in behavioral activation and stereotyped behaviors.
- Neurodegenerative Observations: DA axon terminals in the striatum exhibit changes during degeneration.
Catecholamine Inactivation
- Reuptake Mechanisms:
- Non-selective reuptake:
- DA transporter - impacts rodent behavior in response to psychostimulants.
- NE transporter - genetic deletion increases sensitivity to psychostimulants.
- ADHD medications target reuptake (e.g., methylphenidate (Ritalin), amphetamines (Adderall), tricyclic antidepressants).
- Metabolic Breakdown:
- Enzymatic breakdown by:
- Catechol-O-methyltransferase (COMT): Generates metabolites like homovanillic acid (HVA) from DA and MHPG/VMA from NE.
- Monoamine Oxidase (MAO): Divided into MAO-A and MAO-B.
- Clinical Implications of Inactivation:
- MAO Inhibitors (MAOIs) used in clinical depression (e.g., phenelzine, tranylcypromine).
- Selective MAO-B inhibitors used for Parkinson's disease (e.g., selegiline, rasagiline).
- COMT inhibitors administered alongside L-DOPA for Parkinson's.
Organization & Function of the Dopaminergic System
- Ascending DA System Structure: Originates in brain stem cell groups:
- Nigrostriatal tract
- Mesolimbic pathway
- Mesocortical pathway
- Tuberoinfundibular pathway
- Functions of Dopamine:
- Influenced by evidence from various methodologies (clinical cases, animal studies).
- Dopamine-deficient mouse model details:
- Results in aphagia, adipsia, and hypoactivity normalized by L-DOPA.
- Significance of Dorsal Striatum: Critical in regulating behaviors, motivation, and cognition.
Functions of Dopamine
- Movement Implication:
- Associated with Parkinson’s disease symptoms.
- Other mutations in DA genes lead to Parkinsonian symptoms (e.g., Segawa’s disease, loss-of-function mutations in DA transporter).
- MPTP as a DA neurotoxin causing neurodegeneration.
- Striatum Region Segmentation:
- Ventral: Nucleus accumbens involvement in emotional and reward circuits.
- Dorsal: Caudate nucleus and putamen regulating behavior, attention, and cognitive function via mesocortical pathways.
- Activation by aversive stimuli leading to behavioral arousal and locomotion.
Notable Receptor Subtypes in Dopamine Function
- Dopamine Receptor Types & Functions:
- D1 Receptor: G-protein coupled, facilitates neuronal growth and developing behavioral responses in basal ganglia.
- D2 Receptor: Functions as autoreceptors to modulate responses.
- α2 Receptor: Functions in modulation of symptoms like withdrawal; antagonism leads to heightened anxiety.
- Behavioral Activation and Medication Relationships:
- Drugs like apomorphine target D1 and D2 receptors to influence behavior, inhibition at high doses or antagonist treatments leading to catalepsy.
Dopamine Receptor Subtypes & Experimental Usage
- Gene Manipulation Models:
- Gene knockout, knockin, overexpression, and transgenic animals used to study receptor functions and implications.
- Figure Studies:
- D1 receptor knockout mice show diminished responsiveness to psychostimulants (e.g., cocaine).
Drugs Affecting the Dopaminergic System
| Drug | Mechanism of Action |
|---|
| L-DOPA | Dopamine precursor |
| Carbidopa | Peripheral AADC inhibitor |
| MAO inhibitors | Antidepressants affecting dopamine and serotonin |
| Amphetamines | Catecholamine releaser and reuptake blocker |
| Cocaine | Block DA, NE, 5-HT reuptake |
| Haloperidol | D2 receptor antagonist (antipsychotic) |
Organization & Function of the Noradrenergic System
- Components: Central (CNS) and peripheral (PNS).
- Locus Coeruleus (LC): Central site containing noradrenergic neurons.
- Sends projections across the forebrain and into the cerebellum and spinal cord.
Norepinephrine Function & Receptor Subtypes
- Central Nervous System Functions:
- Modulates sensory input for goal-directed behaviors.
- Adrenergic Receptors:
- Divided into alpha (α) and beta (β) subtypes involved in arousal and cognitive processes.
- Inverted U-Shaped Relationship:
- NE in the PFC enhances attention and working memory performance non-stressfully within limitations of receptor affinity.
Norepinephrine and Stress Response
- Panic Circuit Dynamics:
- Amygdala's role in interpreting fear/stress and activating LC for norepinephrine release, facilitating sympathetic activation.
- Panic Disorder Characteristics:
- Dysfunction in NE feedback mechanisms leads to increased severity of panic symptoms.
- Medication Classes:
- α2-agonists (e.g., clonidine) vs α2-antagonists (e.g., yohimbine) - effects on anxiety management.
Norepinephrine Medications
| Drug | Mechanism of Action |
|---|
| Phenelzine/tranylcypromine | Nonselective MAO inhibitors |
| Atomoxetine | Selective NE reuptake blocker (ADHD treatment) |
| Clonidine | α2-agonist for hypertension, anxiety |
| Propranolol | Nonselective β-receptor antagonist (anxiety) |
Review Questions & Learning Objectives
- Key Concepts to Explore:
- Understanding reversible vs irreversible inhibitors of catecholamine vesicular uptake.
- Comparison between DA-targeting methodologies (genetic engineering vs neurotoxins).
- Examining inverted U-shape relationship for NE in cognitive function and associated receptor implications.
- Mechanisms underlying enhanced consolidation of emotional memories and the role of involved neural circuitry and biochemical processes.